Dragonfly, Tyler Jacks Sign On for Boston’s Life Science Disruptors on Sept. 28

Xconomy Boston — 

Dragonfly Therapeutics is one of the more unusual biotech startups to come along of late. It was formed by well-known cancer researchers on both coasts, backed by some high-powered family offices, and already has a partnership with Celgene—all without the presence or help of a single venture firm.

Two of Dragonfly’s co-founders, cancer research pioneer Tyler Jacks and filmmaker and tech entrepreneur Bill Haney, have joined the lineup for Xconomy’s annual “Boston’s Life Science Disruptors” event on Sept. 28. They’ll give attendees an inside look at the story behind the stealthy startup, insights gleaned from its atypical path, and the road ahead.

Dragonfly is just one of three stories being featured. There is more still to come, but confirmed speakers include:

  • Mary Lynne Hedley, President & Chief Operating Officer, Tesaro
  • Lonnie Moulder, CEO, Tesaro
  • Tyler Jacks, Director, Koch Institute for Integrative Cancer Research at MIT; Co-founder, Dragonfly Therapeutics
  • Bill Haney, Co-founder & CEO, Dragonfly Therapeutics
  • Morris J. Birnbaum, CSO, Internal Medicine and Senior Scientific Director, Pfizer Kendall Square

You can still save $50 on your ticket if you act fast; Xconomy’s discounted rate ends soon so don’t forget to register today and save on regular registration. Don’t miss this great opportunity to save and buy your ticket today!